TY - JOUR
T1 - Synthesis, characterization, and biological relevance of hydroxypyrone and hydroxypyridinone complexes of molybdenum
AU - Lord, Sarah J.
AU - Epstein, Noah A.
AU - Paddock, Robert L.
AU - Vogels, Christopher M.
AU - Hennigar, Tracy L.
AU - Zaworotko, Michael J.
AU - Taylor, Nicholas J.
AU - Driedzic, William R.
AU - Broderick, Tom L.
AU - Westcott, Stephen A.
PY - 1999
Y1 - 1999
N2 - We have prepared a number of complexes of the type cis-MoO2L2 where L represents a hydroxypyronato or hydroxypyridinonato ligand. Both the maltol (3-hydroxy-2-methyl-4-pyrone, Hma) and kojic acid (5-hydroxy-2-hydroxymethyl-4-pyrone, Hka) complexes, cis-MoO2(ma)2 (1) and cis-MoO2(ka)2 (2), have been characterized by X-ray diffraction studies. The pyrone ligands are bound to molybdenum in a cis bidentate fashion via the deprotonated hydroxyl groups and the ketone moieties. Crystals of 1 are orthorhombic, a = 12.107 (1), b = 8.6169 (8), c = 16.472 (1) A, Z = 4, space group Pca21, and those of 2 are monoclinic, a = 8.4591 (5), b = 16.3453 (10), c = 10.2954 (7) A, β = 103.0320 (10)°, Z = 4, space group P21/c. Hydroxypyridinone molybdenum complexes have been prepared for both maltol and kojic acid derivatives with the substituents Me, n-Pr, CH2Ph, Ph at the ring nitrogen. Crystals of the 3-hydroxy-2-methyl-1-phenyl-4-pyridinone (Hppp) derivative, MoO2(ppp)2 (9), are monoclinic, a = 10.9476 (6), b = 13.5353 (9), c = 17.4877 (10) A, β = 93.465 (4)°, Z = 4, space group P21/n. Initial investigations into the effects molybdenum compounds have on diabetic hearts are presented. Both Na2MoO4 (used as a control) and 1 were effective in lowering blood glucose and free fatty acid levels. Diabetic rats treated with molybdate showed significant improvements in postischemic cardiac function.
AB - We have prepared a number of complexes of the type cis-MoO2L2 where L represents a hydroxypyronato or hydroxypyridinonato ligand. Both the maltol (3-hydroxy-2-methyl-4-pyrone, Hma) and kojic acid (5-hydroxy-2-hydroxymethyl-4-pyrone, Hka) complexes, cis-MoO2(ma)2 (1) and cis-MoO2(ka)2 (2), have been characterized by X-ray diffraction studies. The pyrone ligands are bound to molybdenum in a cis bidentate fashion via the deprotonated hydroxyl groups and the ketone moieties. Crystals of 1 are orthorhombic, a = 12.107 (1), b = 8.6169 (8), c = 16.472 (1) A, Z = 4, space group Pca21, and those of 2 are monoclinic, a = 8.4591 (5), b = 16.3453 (10), c = 10.2954 (7) A, β = 103.0320 (10)°, Z = 4, space group P21/c. Hydroxypyridinone molybdenum complexes have been prepared for both maltol and kojic acid derivatives with the substituents Me, n-Pr, CH2Ph, Ph at the ring nitrogen. Crystals of the 3-hydroxy-2-methyl-1-phenyl-4-pyridinone (Hppp) derivative, MoO2(ppp)2 (9), are monoclinic, a = 10.9476 (6), b = 13.5353 (9), c = 17.4877 (10) A, β = 93.465 (4)°, Z = 4, space group P21/n. Initial investigations into the effects molybdenum compounds have on diabetic hearts are presented. Both Na2MoO4 (used as a control) and 1 were effective in lowering blood glucose and free fatty acid levels. Diabetic rats treated with molybdate showed significant improvements in postischemic cardiac function.
KW - Heart function
KW - Hydroxypyridinones
KW - Hydroxypyrones
KW - Molybdenum
UR - http://www.scopus.com/inward/record.url?scp=0033306619&partnerID=8YFLogxK
U2 - 10.1139/v99-111
DO - 10.1139/v99-111
M3 - Article
AN - SCOPUS:0033306619
SN - 0008-4042
VL - 77
SP - 1249
EP - 1261
JO - Canadian Journal of Chemistry
JF - Canadian Journal of Chemistry
IS - 7
ER -
